Loading...
Market
Story
UK Patient First to Receive Experimental Lung Cancer Vaccine in Global Trial
Aug 23, 2024, 04:19 AM
A lung cancer patient in the UK has become the first to receive an experimental vaccine as part of a world-first trial. This pioneering trial, conducted across seven countries, aims to explore new treatments for lung cancer. The patient, whose cancer was found by coincidence, received the vaccine at UCLH. This development offers hope in the fight against the disease, marking a significant step in medical research. The trial has garnered attention and is featured on the front page of several publications, highlighting its potential impact on future cancer treatments.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant survival improvement • 25%
Partial survival improvement • 25%
No significant change • 25%
Deterioration • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
